Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Adv Pharmacol. 2014 Aug 22;71:203–243. doi: 10.1016/bs.apha.2014.06.002

Figure 7.

Figure 7

111In-ibritumomab to assess delivery and 90Y-ibritumomab to assess efficacy in refractory primary CNS lymphoma. (A) Brain MRI, gadolinium-enhanced T1 axial view, 11 days prior to 111In-ibritumomab showing large enhancing tumor in the genu of the corpus callosum. (B) Brain axial SPECT image, 48 h after 5.2 mCi of 111In-ibritumomab showing uptake in the genu of the corpus callosum. (C) Brain MRI, gadolinium-enhanced T1 axial view, 8 weeks after 5.2 mCi of 111In- and 23.1 mCi of 90Y-ibritumomab showing progressive disease distant from the genu of the corpus callosum. Reproduced with permission from Doolittle et al. (2007), © 2007 Informa Healthcare.